TICKERNOMICS Sign up
Last Update: 2024-03-28 02:08:55
PFIZER INC ( PFE ) https://www.pfizer.com
27.59USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-26.81%
PFE
SPY
32.74%
-8.78%
PFE
SPY
92.93%
-2.40%
PFE
SPY
224.41%
PFE
91.65%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
156168.36
178927.36
30.29
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
10.52
2.00
1.75
2.08
6.07
17.47
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-14.98
29.95
17.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.4707
-2.36
-4.75
0.59
Other Earnings and Cash Flow Stats:
PFIZER INC ( PFE ) Net Income TTM ($MM) is 10483.00
PFIZER INC ( PFE ) Operating Income TTM ($MM) is 22170.00
PFIZER INC ( PFE ) Owners' Earnings Annual ($MM) is 17745.21
PFIZER INC ( PFE ) Current Price to Owners' Earnings ratio is 9.16
PFIZER INC ( PFE ) EBITDA TTM ($MM) is 26377.00
PFIZER INC ( PFE ) EBITDA Margin is 17.82%
Capital Allocation:
PFIZER INC ( PFE ) has paid 1.68 dividends per share and bought back 87.0 million shares in the past 12 months
PFIZER INC ( PFE ) has increased its debt by 25018.0 million USD in the last 12 months
Capital Structure:
PFIZER INC ( PFE ) Interest-bearing Debt ($MM) as of last quarter is 63792
PFIZER INC ( PFE ) Annual Working Capital Investments ($MM) are -10730
PFIZER INC ( PFE ) Book Value ($MM) as of last quarter is 89288
PFIZER INC ( PFE ) Debt/Capital as of last quarter is 71%
Other Balance Sheet Stats:
PFIZER INC ( PFE ) has 2853 million in cash on hand as of last quarter
PFIZER INC ( PFE ) has 47794 million of liabilities due within 12 months, and long term debt 63792 as of last quarter
PFIZER INC ( PFE ) has 5646 common shares outstanding as of last quarter
PFIZER INC ( PFE ) has 0 million USD of preferred stock value
Academic Scores:
PFIZER INC ( PFE ) Altman Z-Score is 1.73 as of last quarter
PFIZER INC ( PFE ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
PFIZER INC ( PFE ) largest shareholder is T. Rowe Price Associates, Inc. owning 30544057 shares at 842.71 ($MM) value
Earl Blumenauer(an insider) Bought 0 shares of PFIZER INC ( PFE ) for the amount of $0.00 on 2024-02-12
0.04% of PFIZER INC ( PFE ) is held by insiders, and 70.35% is held by institutions
PFIZER INC ( PFE ) went public on 2012-08-13
Other PFIZER INC ( PFE ) financial metrics:
FCF:15658.00
Unlevered Free Cash Flow:20754.00
EPS:-1.69
Operating Margin:-14.98
Gross Profit Margin:29.95
Div. Payout Ratio%:63.89
Div. Growth YoY%:4.35
Equity Return%:-10.70
Beta:0.59
Buffet's Owners Earnings:17745.21
Price to Owner's Earnings:9.16
About PFIZER INC ( PFE ) :
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.